Physician profile
Emily C Bier
NPI 1043268196
$2,197.09
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,576 · 2020: $621.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $278.81 | 2019-2020 | |
| Glaxosmithkline, LLC. | $230.91 | 2019-2020 | |
| Astellas Pharma US INC | $196.60 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.26 | 2019-2020 | |
| Novo Nordisk INC | $146.08 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $137.87 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $133.42 | 2019 | |
| Amgen INC. | $101.46 | 2019-2020 | |
| Lilly USA, LLC | $81.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $80.73 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $79.42 | 2019-2020 | |
| Sanofi Pasteur INC. | $76.58 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $67.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $61.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.84 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $41.85 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $40.74 | 2019 | |
| Amarin Pharma, INC. | $36.37 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $35.42 | 2020 | |
| Arbor Pharmaceuticals, INC. | $34.24 | 2019-2020 | |
| Antares Pharma, INC. | $26.03 | 2019 | |
| Philips North America LLC | $20.08 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.98 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.15 | 2019 | |
| Eisai INC. | $14.56 | 2020 | |
| Hikma Pharmaceuticals USA | $14.53 | 2019 | |
| Circassia INC. | $10.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Bier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.